Biodesix Brings Series E To $14.4M

Boulder-based Biodesix, the molecular diagnostics and personalized medicine company which is initially focused on lung cancer testing has raised another $6.1M in funding in its Series E round, bringing the total raised in the funding to $14.4M. According to Biodesix , the new funds came from existing shareholders. Biodesix had announced $8.3M in the funding round last month. The company said the round will remain open to its current shareholders until September. Biodesix is using the new funding to expand development, sales, and marketing efforts for VeriStrat, its molecular diagnostics protein test which is aimed at helping physicians with the treatment of advanced non-small cell lung cancer (NSCLC). More information »